Novacyt SA
LSE:NCYT
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Novacyt SA
PAR:ALNOV
|
26.9m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.9B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
37.5B EUR |
Loading...
|
Market Distribution
| Min | -147 400% |
| 30th Percentile | -2.2% |
| Median | 2.6% |
| 70th Percentile | 7.1% |
| Max | 14 243.8% |
Other Profitability Ratios
Novacyt SA
Glance View
Novacyt SAS engages in the development and sale of cancer and infectious disease diagnostic products. The company is headquartered in Velizy-Villacoublay, Ile-De-France. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The firm provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The firm creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Novacyt SA is -159.2%, which is above its 3-year median of -235%.
Over the last 3 years, Novacyt SA’s Net Margin has decreased from -10.1% to -159.2%. During this period, it reached a low of -322.5% on Jun 30, 2023 and a high of -10.1% on Jun 30, 2022.
